Advertisement

Investigational New Drugs

, Volume 25, Issue 1, pp 85–94 | Cite as

Phase II trial of nolatrexed dihydrochloride [ThymitaqTM, AG 337] in patients with advanced hepatocellular carcinoma

  • Minaxi JhawerEmail author
  • Lee Rosen
  • Janet Dancey
  • Howard Hochster
  • Solomon Hamburg
  • Margaret Tempero
  • Neil Clendeninn
  • Sridhar Mani
Phase II Studies

Summary

Background: To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma.

Patients and methods: Forty-eight patients were entered onto this study. Nolatrexed was administered every 3 weeks as a 24-h continuous intravenous infusion of 725 mg/m2/day for 5 days. Doses were adjusted to maintain a dose level that produced grade 2 toxicity. Response was assessed after every two cycles. Plasma pharmacokinetic samples were assayed using a validated high performance liquid chromatography ultraviolet method.

Results: Thirty-nine (81%) patients were evaluable for response. The mean number of cycles received was 2.8 (range 1–12). The mean dose intensity was 700 mg/m2/day (SD of 71). One patient had a partial response (2.6%) for 7 months. Eighteen (46%) patients had SD, 20 (51%) patients had progressive disease. The median duration of SD was 93 days. The median overall survival was 32 weeks [95% CI (22–37)]. The most frequent Grade 3 or 4 adverse events were stomatitis (25%), dehydration (23%) and asthenia (21%). There was no evidence of cumulative toxicity. The overall median plasma concentration (Cmax) was 14.20 μg/mL (range 1.41 to 119 μg /mL) with no accumulation observed between cycles 1–6.

Conclusion: This phase II study of nolatrexed in advanced HCC patients, demonstrated minimal activity and significant stomatitis. Hence, it does not warrant further study as a single agent for this disease.

Keywords

Hepatocellular carcinoma Thymidylate synthase inhibitors Thymitaq Phase II clinical trial 

Notes

Acknowledgments

We would like to thank all the physicians, patients and staff at Agouron Pharmaceuticals, Inc. La Jolla, CA and Eximias Pharmaceutical Corporation, Berwyn, PA involved in this study.

References

  1. 1.
    American Cancer Society (2005) Cancer facts and figures 2005. American Cancer Society, Atlanta, GAGoogle Scholar
  2. 2.
    Thomas M, Zhu A (2005) Hepatocellular carcinoma: The need for progress. J Clin Oncol 23(13):2982–2899CrossRefGoogle Scholar
  3. 3.
    Physician's Data Query (1993) Adult primary liver cancer (computer program). National Cancer InstituteGoogle Scholar
  4. 4.
    Lotze MT, Flickinger JC, Carr BI (1993) Hepatobiliary neoplasms. In: De Vita VT, Hellman S (eds) Cancer principles and practice of oncology. JB Lippincott, Philadelphia pp 883–913Google Scholar
  5. 5.
    Tsukuma H, Hiyama T, Tanaka S (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801PubMedCrossRefGoogle Scholar
  6. 6.
    Parkin DM, Whelan SL, Ferlay J et al (eds) (1997) Cancer incidence in five continents, vol VII. International agency for research on cancer, Lyon, FranceGoogle Scholar
  7. 7.
    A new prognostic system for hepatocellular carcinoma (1998) A retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28:751Google Scholar
  8. 8.
    Di Bisceglie AM, Carithers Jr RL, Gores GJ (1998) Hepatocellular carcinoma. Hepatology 28(4):1161–1165PubMedCrossRefGoogle Scholar
  9. 9.
    Sitzmann JV, Order SE, Klein JL (1987) Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5:1566–1573PubMedGoogle Scholar
  10. 10.
    Venook A (1994) Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 12:1324–1334Google Scholar
  11. 11.
    Ihde DC, Kane RC, Cohen MH (1977) Adriamycin therapy in American patients with hepatocellular carcinoma. Can Treat Rep 61:1385Google Scholar
  12. 12.
    Tetef M, Doroshow J, Akman S (1995) 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13:460PubMedGoogle Scholar
  13. 13.
    Yang TS, Lin YC, Chen JS (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750PubMedCrossRefGoogle Scholar
  14. 14.
    Yang TS, Chang WC, Lin YC (2003) A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma (abstract). Proc Am Soc Clin Oncol 22:336aGoogle Scholar
  15. 15.
    Lee J, Park JO, Kim WS (2004) Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 54:385PubMedCrossRefGoogle Scholar
  16. 16.
    Yeo W, Mok TS, Zee B (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532PubMedCrossRefGoogle Scholar
  17. 17.
    Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, Aherne GW (2000) Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Can Res 6:2538–2546Google Scholar
  18. 18.
    Webber SE, Bleckman TM, Attard J (1993) Design of thymidylate synthase inhibitors using protein crystal-structures—The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36:733–746PubMedCrossRefGoogle Scholar
  19. 19.
    Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA, Shetty BV (1996) AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Can Chemother Pharmacol 37:509–517CrossRefGoogle Scholar
  20. 20.
    Rafi I, Taylor GA, Calvette JA (1995) Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG 337) given by 24 hour continuous intravenous infusion. Clin Cancer Res 1:275–1284Google Scholar
  21. 21.
    Rafi I, Boddy AV, Calvete JA, Taylor GA et al (1998) Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol 160:1131–1141Google Scholar
  22. 22.
    Loh KK, Cohn A, Kelly K (1996) Phase II trials of thymitaq (AG337) in six solid tumor diseases. Proc Am Soc Clin Onc 15:183Google Scholar
  23. 23.
    Belani CP, Agarwal S, Johnson J, Cohn A, Bernstein J, Langer C (1997) A phase II clinical trial of Thymitaq (AG337) in patients with squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 16:1381aGoogle Scholar
  24. 24.
    Stuart KE, Hajdenberg J, Cohn A (1996) A phase II trial of thymitaq (AG337) in patients with hepatocellular carcinoma. Proc Am Soc Clin Onc 15:202Google Scholar
  25. 25.
    Eximias Pharmaceutical Corporation, Investigator's Brochure (2005) Version VIIGoogle Scholar
  26. 26.
    World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. World health organization, Geneva, SwitzerlandGoogle Scholar
  27. 27.
    The Cancer Therapy Evaluation Program: Common toxicity criteria manual, 8/99 update. http://ctep.info.nih.gov/CTC3/CTC-Manual.htmGoogle Scholar
  28. 28.
    Gehan EA (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346–353PubMedCrossRefGoogle Scholar
  29. 29.
    Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079–1085PubMedGoogle Scholar
  30. 30.
    Bland MJ, Altman DG (1998) Survival probabilities the Kaplan-Meier method. BMJ 317:1572–1580Google Scholar
  31. 31.
    Rafi BV, Calvete JA, Newell DR, Bailey NP, Lind MJ, Green M, Hines J, Johnstone A, Clendeninn N, Calvert AH (1998) Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Onco l16(3):1131–1134Google Scholar
  32. 32.
    Falkson G, Moertel CG, Lavin P (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149PubMedCrossRefGoogle Scholar
  33. 33.
    Choi TK, Lee NW, Wong J (1984) Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53:401PubMedCrossRefGoogle Scholar
  34. 34.
    Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 51:206PubMedCrossRefGoogle Scholar
  35. 35.
    Czauderna P, Mackinlay G, Perilongo G (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20:2798PubMedCrossRefGoogle Scholar
  36. 36.
    Drori S, Jansen G, Mauritz R, Peters G, Assaraf Y (2000) Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Bio Chem 275(40):30855–30863CrossRefGoogle Scholar
  37. 37.
    Porta C, Ruff P, Feld R, Feun L, Jeziorski K, Leighton J, Senico P, Gallo J, Kennealey G (2005) Results of a phase III randomized controlled study, the largest ever completed in Hepatocellular Carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with Nolatrexed (NOL) or Doxorubicin (DOX). Presented at GI ASCOGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Minaxi Jhawer
    • 1
    Email author
  • Lee Rosen
    • 2
  • Janet Dancey
    • 3
  • Howard Hochster
    • 4
  • Solomon Hamburg
    • 5
  • Margaret Tempero
    • 6
  • Neil Clendeninn
    • 7
  • Sridhar Mani
    • 1
  1. 1.Montefiore Medical CenterNYUSA
  2. 2.Premiere OncologyCAUSA
  3. 3.National Cancer InstituteMDUSA
  4. 4.New York University Medical CenterNYUSA
  5. 5.Twr Hematology Oncology Medical GroupCAUSA
  6. 6.University of CaliforniaSan FranciscoUSA
  7. 7.HanaleiUSA

Personalised recommendations